Literature DB >> 17266201

Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.

Ismail Salama1, Carsten Hocke, Wolfgang Utz, Olaf Prante, Frank Boeckler, Harald Hübner, Torsten Kuwert, Peter Gmeiner.   

Abstract

Elucidation of the physiological role of the D3 receptor and its distribution in the brain using positron emission tomography (PET) is hampered by the lack of bioavailable subtype selective tracer ligands. To develop appropriate D3 radioligands, we designed an integrative procedure involving the elucidation of structural features determining D3 selectivity over both congeners D2 and D4 by comparative molecular analysis. Thus, we have successfully generated CoMFA and CoMSIA models based on the affinitiy differences of a series of 79 ligands representing a broad range of selectivities. These models yielded highly significant cross-validations (q2cv(D3/D2) = 0.86; q2cv(D3/D4) = 0.92) and excellent predictions of a 16-ligand test set (r2pred = 0.79-0.93). Exploiting this information, synthesis and receptor binding studies directed us to the fluorinated lead compounds 78 and 79, featuring subnanomolar D3 affinities and considerable selectivities over D2 and D4 and, subsequently, to the subtype selective PET tracers [18F]78 and [18F]79.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266201     DOI: 10.1021/jm0611152

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

2.  A general and efficient method for the Suzuki-Miyaura coupling of 2-pyridyl nucleophiles.

Authors:  Kelvin L Billingsley; Stephen L Buchwald
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

Review 3.  Software and resources for computational medicinal chemistry.

Authors:  Chenzhong Liao; Markus Sitzmann; Angelo Pugliese; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2011-06       Impact factor: 3.808

Review 4.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

5.  Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods.

Authors:  Qi Wang; Robert H Mach; Robert R Luedtke; David E Reichert
Journal:  J Chem Inf Model       Date:  2010-10-11       Impact factor: 4.956

Review 6.  Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.

Authors:  Vertika Gautam; Anand Gaurav; Neeraj Masand; Vannajan Sanghiran Lee; Vaishali M Patil
Journal:  Mol Divers       Date:  2022-07-11       Impact factor: 3.364

7.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.

Authors:  Yongkai Cao; Ningning Sun; Jiumei Zhang; Zhiguo Liu; Yi-Zhe Tang; Zhengzhi Wu; Kyeong-Man Kim; Seung Hoon Cheon
Journal:  Medchemcomm       Date:  2018-06-14       Impact factor: 3.597

8.  A two-step target binding and selectivity support vector machines approach for virtual screening of dopamine receptor subtype-selective ligands.

Authors:  Jingxian Zhang; Bucong Han; Xiaona Wei; Chunyan Tan; Yuzong Chen; Yuyang Jiang
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

9.  Site-selective Suzuki-Miyaura coupling of heteroaryl halides - understanding the trends for pharmaceutically important classes.

Authors:  Joshua Almond-Thynne; David C Blakemore; David C Pryde; Alan C Spivey
Journal:  Chem Sci       Date:  2016-08-09       Impact factor: 9.825

Review 10.  An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs.

Authors:  Kenneth Lundstrom
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.